Mannkind Corp (MNKD) 3.05 $MNKD
Another Month, Another Crushing Decline for MannKind
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 06, 6:05AM CDT
MNKD data by YCharts . Shares of MannKind , the biotechnology company behind the revolutionary inhaled diabetes drug Afrezza, plunged by double-digits yet again on a monthly basis, dropping 15% in September based on data from S&P Capital...
SNY: 48.75 (+0.03), MNKD: 3.05 (+0.04)
MannKind Silent on Debt Conversion, Suggesting Costly Cash Settlement
at The Street - Mon Oct 05, 11:53AM CDT
Using cash to settle the debt was MannKind's worst-case option because it leaves the company with little money to fund ongoing operations.
SNY: 48.75 (+0.03), MNKD: 3.05 (+0.04)
MannKind to Present at Aegis Capital Corp. 2015 Growth Conference
GlobeNewswire - Mon Oct 05, 8:00AM CDT
MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the Aegis Capital Corp. 2015 Growth Conference on Thursday, October 8, 2015 at 9:30 am Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada.
MNKD: 3.05 (+0.04)
MannKind Cuts Its Headcount, But Will It Matter?
Todd Campbell, The Motley Fool - Motley Fool - Thu Oct 01, 12:36PM CDT
Source: MannKind MannKind continues to cut its expenses in response to a slower-than-hoped ramp up in sales for its inhalable insulin Afrezza; however, the pace of cuts may not be steep enough to matter if sales don't begin to materialize...
SNY: 48.75 (+0.03), MNKD: 3.05 (+0.04)
Scanning the Pulse of the Healthcare Stocks - ZIOPHARM Oncology, VIVUS, Keryx Biopharmaceuticals, MannKind and Ovascience
PR Newswire - Wed Sep 30, 11:56AM CDT
ACI Association has initiated research coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), VIVUS, Inc. (NASDAQ: VVUS), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), MannKind Corporation (NASDAQ: MNKD), and Ovascience Inc. (NASDAQ: OVAS). On Tuesday, September 29, 2015, Nasdaq ended at 4,517.32, down 0.59%, Dow Jones advanced 0.30% to finish the day at 16,049.13, and the S&P closed at 1,884.09, up 0.12%. Register for your complimentary reports at the links given below.
ZIOP: 10.92 (+0.32), OVAS: 12.25 (+1.00), VVUS: 2.00 (unch), MNKD: 3.05 (+0.04), KERX: 4.25 (+0.23)
Interesting MNKD Put And Call Options For May 2016
DividendChannel.com - Thu Sep 24, 12:09PM CDT
Investors in MannKind Corp saw new options begin trading this week, for the May 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly...
MNKD: 3.05 (+0.04)
These Healthcare Stocks Could Be Primed for a Short Squeeze
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 23, 3:01PM CDT
Source: Centers for Disease Control and Prevention. As a whole, healthcare stocks have handily outperformed the broader market over the past five years. But as the idiom goes, "the bigger they are, the harder they fall." Because healthcare...
MYGN: 39.19 (-0.19), INSY: 25.65 (+0.64), MNKD: 3.05 (+0.04)
Technical Briefing on Biotechnology Equities -- MannKind, Novavax, Incyte, BioMarin Pharma, and Sangamo Biosciences
PR Newswire - Wed Sep 23, 7:06AM CDT
Equity Research Institute has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Novavax Inc. (NASDAQ: NVAX), Incyte Corporation (NASDAQ: INCY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Sangamo Biosciences Inc. (NASDAQ: SGMO). Free research report on MannKind can be accessed at https://www.erionline.net/MNKD.pdf On Tuesday, September 22, 2015, the NASDAQ Composite ended at 4,756.72, down 1.50%, the Dow Jones Industrial Average lost 1.09%, to finish the day at 16,330.47, and the S&P 500 closed at 1,942.74, down 1.23%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
BMRN: 102.69 (+1.97), NVAX: 8.04 (+0.43), INCY: 105.00 (+1.56), SGMO: 5.94 (+0.38), MNKD: 3.05 (+0.04)
Critical Alerts For Tesla Motors, Denbury Resources, MannKind, SolarCity and Under Armour Released By InvestorsObserver
PR Newswire - Tue Sep 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, DNR, MNKD, SCTY and UA.
UA: 102.32 (+1.18), TSLA: 220.69 (-6.03), SCTY: 48.94 (+1.83), DNR: 3.72 (-0.14), MNKD: 3.05 (+0.04)
3 Investing Myths, Debunked!
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Fri Sep 18, 11:40AM CDT
Photo by StockMonkeys.com / Flickr creative commons Over the long-term, the stock market has created a substantial amount of wealth for those who have been brave enough to put their hard-earned money at risk. However, learning how to invest wisely...
MNKD: 3.05 (+0.04), ARNA: 2.19 (+0.14)
3 Dangerous Biotech Stocks
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Sep 13, 12:15PM CDT
Source: Images of Money via Flickr Creative Commons. Given their enormous cash burn and long development cycles, biotech stocks tend to be a very risky bunch. However, not all biotech stocks are created equally, as they all exists on a risk...
GALE: 1.74 (+0.01), AEGR: 14.61 (+0.30), MNKD: 3.05 (+0.04)
Is It Time to Kick These Healthcare Laggards Out of Your Portfolio?
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Sep 13, 6:02AM CDT
I ( Brian Feroldi here!) know firsthand just how painful it can be to sell a stock that has lost you money. And whenever it happens I get that nagging feeling in the back of my mind that if I just hang in there, the stock will come back and I will...
ISIS: 43.24 (+0.86), ABBV: 55.64 (-0.40), MNKD: 3.05 (+0.04)
Why MannKind Corporation Fell 11% in August
Brian Feroldi, The Motley Fool - Motley Fool - Fri Sep 11, 6:42AM CDT
What: Shares of MannKind , a biopharmaceutical company focused on developing medicines to treat diabetes, were pummeled in August as the company shed more than 11% of its value during the month, according data from S&P Capital IQ . So...
MNKD: 3.05 (+0.04)
Critical Alerts For Netflix, MannKind, Arrowhead Research, Google Inc. and CyberArk Software Released By InvestorsObserver
PR Newswire - Thu Sep 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for NFLX, MNKD, ARWR, GOOG and CYBR.
NFLX: 113.33 (-1.60), CYBR: 52.91 (-0.46), ARWR: 5.89 (+0.13), MNKD: 3.05 (+0.04), GOOG: 643.61 (+4.45)
MannKind Down 7.9%, Shares Slide into the Red (MNKD)
Comtex SmarTrend(R) - Wed Sep 09, 12:47PM CDT
MannKind (NASDAQ:MNKD) is one of today's worst performing low-priced stocks, down 7.9% to $3.75 on 1.1x average daily volume. Thus far today, MannKind has traded 6.0 million shares, vs. average volume of 5.6 million shares per day. The stock has underperformed the Dow (-7.9% to the Dow's -0.3%) and underperformed the S&P 500 (-7.9% to the S&P's -0.2%) during today's trading.
MNKD: 3.05 (+0.04)
Analysts' Actions -- Mannkind, Micron, Ciena, Finisar and More
at The Street - Wed Sep 09, 7:56AM CDT
Here are Wednesday's top research calls, including ratings changes for Mannkind, Micron, Ciena and Finisar.
FNSR: 11.80 (+0.06), FIT: 35.36 (+0.69), MU: 18.16 (-0.56), TSLA: 220.69 (-6.03), TTPH: 9.38 (+0.08), MNKD: 3.05 (+0.04), CIEN: 22.75 (+0.05), SCTY: 48.94 (+1.83), R: 75.88 (+0.75), DG: 67.23 (+1.03), TEX: 20.57 (+0.01), BEN: 38.85 (-0.04), BK: 40.45 (-0.42), BABA: 68.71 (+1.01)
Downgrade Alert for MannKind (MNKD)
Comtex SmarTrend(R) - Wed Sep 09, 7:14AM CDT
MannKind (NASDAQ:MNKD) was downgraded from Neutral to Underweight at Piper Jaffray today. The stock closed yesterday at $4.07 on volume of 4.3 million shares, below average daily volume of 5.6 million. MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Companys lead investigational product candidate is the Technosphere Insulin System.
MNKD: 3.05 (+0.04)
3 Stocks to Avoid This Fall
Matthew Frankel, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Sat Sep 05, 5:18AM CDT
Source: Flickr user Eugene Zemlyanskiy . With the recent drop in the market, there are certainly some attractively priced investment opportunities to be found. However, there are several stocks we're staying away from. Here's why three of our...
NYCB: 18.51 (-0.17), LLY: 86.14 (+2.37), MNKD: 3.05 (+0.04)
MannKind Announces Renewal of Shelf Registration and ATM Agreements
GlobeNewswire - Fri Sep 04, 6:27PM CDT
MannKind Corporation (NASDAQ:MNKD) today announced the renewal of its shelf Registration Statement on Form S-3, as filed with the Securities and Exchange Commission, replacing the previous shelf which expired on August 31, 2015. Concurrently, MannKind also renewed its At-The-Market Issuance Sales Agreements with Meyers Associates, L.P. (now doing business as BP Capital, a division of Meyers Associates, L.P.) and with MLV & Co. LLC providing for sales, from time to time, of the Company's common stock.
MNKD: 3.05 (+0.04)
The Numbers Behind Biotech's Horrible, No Good, Awful August
at The Street - Tue Sep 01, 6:27AM CDT
Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.
BLUE: 88.80 (+0.30), ZIOP: 10.92 (+0.32), OPK: 8.90 (+0.26), NK: 13.09 (-0.21), KITE: 63.33 (+0.26), ONCE: 49.30 (+1.86), CLDX: 12.80 (+1.06), XON: 36.01 (+1.24), IBB: 308.45 (+1.25), JUNO: 48.64 (+0.84), TWTR: 30.85 (+0.53), MNKD: 3.05 (+0.04)
Another Month, Another Crushing Decline for MannKind
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 06, 6:05AM CDT
MNKD data by YCharts . Shares of MannKind , the biotechnology company behind the revolutionary inhaled diabetes drug Afrezza, plunged by double-digits yet again on a monthly basis, dropping 15% in September based on data from S&P Capital...
SNY: 48.75 (+0.03), MNKD: 3.05 (+0.04)
MannKind Silent on Debt Conversion, Suggesting Costly Cash Settlement
at The Street - Mon Oct 05, 11:53AM CDT
Using cash to settle the debt was MannKind's worst-case option because it leaves the company with little money to fund ongoing operations.
SNY: 48.75 (+0.03), MNKD: 3.05 (+0.04)
MannKind to Present at Aegis Capital Corp. 2015 Growth Conference
GlobeNewswire - Mon Oct 05, 8:00AM CDT
MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the Aegis Capital Corp. 2015 Growth Conference on Thursday, October 8, 2015 at 9:30 am Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada.
MNKD: 3.05 (+0.04)
MannKind Cuts Its Headcount, But Will It Matter?
Todd Campbell, The Motley Fool - Motley Fool - Thu Oct 01, 12:36PM CDT
Source: MannKind MannKind continues to cut its expenses in response to a slower-than-hoped ramp up in sales for its inhalable insulin Afrezza; however, the pace of cuts may not be steep enough to matter if sales don't begin to materialize...
SNY: 48.75 (+0.03), MNKD: 3.05 (+0.04)
Scanning the Pulse of the Healthcare Stocks - ZIOPHARM Oncology, VIVUS, Keryx Biopharmaceuticals, MannKind and Ovascience
PR Newswire - Wed Sep 30, 11:56AM CDT
ACI Association has initiated research coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), VIVUS, Inc. (NASDAQ: VVUS), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), MannKind Corporation (NASDAQ: MNKD), and Ovascience Inc. (NASDAQ: OVAS). On Tuesday, September 29, 2015, Nasdaq ended at 4,517.32, down 0.59%, Dow Jones advanced 0.30% to finish the day at 16,049.13, and the S&P closed at 1,884.09, up 0.12%. Register for your complimentary reports at the links given below.
ZIOP: 10.92 (+0.32), OVAS: 12.25 (+1.00), VVUS: 2.00 (unch), MNKD: 3.05 (+0.04), KERX: 4.25 (+0.23)
Interesting MNKD Put And Call Options For May 2016
DividendChannel.com - Thu Sep 24, 12:09PM CDT
Investors in MannKind Corp saw new options begin trading this week, for the May 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly...
MNKD: 3.05 (+0.04)
These Healthcare Stocks Could Be Primed for a Short Squeeze
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 23, 3:01PM CDT
Source: Centers for Disease Control and Prevention. As a whole, healthcare stocks have handily outperformed the broader market over the past five years. But as the idiom goes, "the bigger they are, the harder they fall." Because healthcare...
MYGN: 39.19 (-0.19), INSY: 25.65 (+0.64), MNKD: 3.05 (+0.04)
Technical Briefing on Biotechnology Equities -- MannKind, Novavax, Incyte, BioMarin Pharma, and Sangamo Biosciences
PR Newswire - Wed Sep 23, 7:06AM CDT
Equity Research Institute has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Novavax Inc. (NASDAQ: NVAX), Incyte Corporation (NASDAQ: INCY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Sangamo Biosciences Inc. (NASDAQ: SGMO). Free research report on MannKind can be accessed at https://www.erionline.net/MNKD.pdf On Tuesday, September 22, 2015, the NASDAQ Composite ended at 4,756.72, down 1.50%, the Dow Jones Industrial Average lost 1.09%, to finish the day at 16,330.47, and the S&P 500 closed at 1,942.74, down 1.23%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
BMRN: 102.69 (+1.97), NVAX: 8.04 (+0.43), INCY: 105.00 (+1.56), SGMO: 5.94 (+0.38), MNKD: 3.05 (+0.04)
Critical Alerts For Tesla Motors, Denbury Resources, MannKind, SolarCity and Under Armour Released By InvestorsObserver
PR Newswire - Tue Sep 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, DNR, MNKD, SCTY and UA.
UA: 102.32 (+1.18), TSLA: 220.69 (-6.03), SCTY: 48.94 (+1.83), DNR: 3.72 (-0.14), MNKD: 3.05 (+0.04)
3 Investing Myths, Debunked!
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Fri Sep 18, 11:40AM CDT
Photo by StockMonkeys.com / Flickr creative commons Over the long-term, the stock market has created a substantial amount of wealth for those who have been brave enough to put their hard-earned money at risk. However, learning how to invest wisely...
MNKD: 3.05 (+0.04), ARNA: 2.19 (+0.14)
3 Dangerous Biotech Stocks
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Sep 13, 12:15PM CDT
Source: Images of Money via Flickr Creative Commons. Given their enormous cash burn and long development cycles, biotech stocks tend to be a very risky bunch. However, not all biotech stocks are created equally, as they all exists on a risk...
GALE: 1.74 (+0.01), AEGR: 14.61 (+0.30), MNKD: 3.05 (+0.04)
Is It Time to Kick These Healthcare Laggards Out of Your Portfolio?
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Sep 13, 6:02AM CDT
I ( Brian Feroldi here!) know firsthand just how painful it can be to sell a stock that has lost you money. And whenever it happens I get that nagging feeling in the back of my mind that if I just hang in there, the stock will come back and I will...
ISIS: 43.24 (+0.86), ABBV: 55.64 (-0.40), MNKD: 3.05 (+0.04)
Why MannKind Corporation Fell 11% in August
Brian Feroldi, The Motley Fool - Motley Fool - Fri Sep 11, 6:42AM CDT
What: Shares of MannKind , a biopharmaceutical company focused on developing medicines to treat diabetes, were pummeled in August as the company shed more than 11% of its value during the month, according data from S&P Capital IQ . So...
MNKD: 3.05 (+0.04)
Critical Alerts For Netflix, MannKind, Arrowhead Research, Google Inc. and CyberArk Software Released By InvestorsObserver
PR Newswire - Thu Sep 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for NFLX, MNKD, ARWR, GOOG and CYBR.
NFLX: 113.33 (-1.60), CYBR: 52.91 (-0.46), ARWR: 5.89 (+0.13), MNKD: 3.05 (+0.04), GOOG: 643.61 (+4.45)
MannKind Down 7.9%, Shares Slide into the Red (MNKD)
Comtex SmarTrend(R) - Wed Sep 09, 12:47PM CDT
MannKind (NASDAQ:MNKD) is one of today's worst performing low-priced stocks, down 7.9% to $3.75 on 1.1x average daily volume. Thus far today, MannKind has traded 6.0 million shares, vs. average volume of 5.6 million shares per day. The stock has underperformed the Dow (-7.9% to the Dow's -0.3%) and underperformed the S&P 500 (-7.9% to the S&P's -0.2%) during today's trading.
MNKD: 3.05 (+0.04)
Analysts' Actions -- Mannkind, Micron, Ciena, Finisar and More
at The Street - Wed Sep 09, 7:56AM CDT
Here are Wednesday's top research calls, including ratings changes for Mannkind, Micron, Ciena and Finisar.
FNSR: 11.80 (+0.06), FIT: 35.36 (+0.69), MU: 18.16 (-0.56), TSLA: 220.69 (-6.03), TTPH: 9.38 (+0.08), MNKD: 3.05 (+0.04), CIEN: 22.75 (+0.05), SCTY: 48.94 (+1.83), R: 75.88 (+0.75), DG: 67.23 (+1.03), TEX: 20.57 (+0.01), BEN: 38.85 (-0.04), BK: 40.45 (-0.42), BABA: 68.71 (+1.01)
Downgrade Alert for MannKind (MNKD)
Comtex SmarTrend(R) - Wed Sep 09, 7:14AM CDT
MannKind (NASDAQ:MNKD) was downgraded from Neutral to Underweight at Piper Jaffray today. The stock closed yesterday at $4.07 on volume of 4.3 million shares, below average daily volume of 5.6 million. MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Companys lead investigational product candidate is the Technosphere Insulin System.
MNKD: 3.05 (+0.04)
3 Stocks to Avoid This Fall
Matthew Frankel, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Sat Sep 05, 5:18AM CDT
Source: Flickr user Eugene Zemlyanskiy . With the recent drop in the market, there are certainly some attractively priced investment opportunities to be found. However, there are several stocks we're staying away from. Here's why three of our...
NYCB: 18.51 (-0.17), LLY: 86.14 (+2.37), MNKD: 3.05 (+0.04)
MannKind Announces Renewal of Shelf Registration and ATM Agreements
GlobeNewswire - Fri Sep 04, 6:27PM CDT
MannKind Corporation (NASDAQ:MNKD) today announced the renewal of its shelf Registration Statement on Form S-3, as filed with the Securities and Exchange Commission, replacing the previous shelf which expired on August 31, 2015. Concurrently, MannKind also renewed its At-The-Market Issuance Sales Agreements with Meyers Associates, L.P. (now doing business as BP Capital, a division of Meyers Associates, L.P.) and with MLV & Co. LLC providing for sales, from time to time, of the Company's common stock.
MNKD: 3.05 (+0.04)
The Numbers Behind Biotech's Horrible, No Good, Awful August
at The Street - Tue Sep 01, 6:27AM CDT
Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.
BLUE: 88.80 (+0.30), ZIOP: 10.92 (+0.32), OPK: 8.90 (+0.26), NK: 13.09 (-0.21), KITE: 63.33 (+0.26), ONCE: 49.30 (+1.86), CLDX: 12.80 (+1.06), XON: 36.01 (+1.24), IBB: 308.45 (+1.25), JUNO: 48.64 (+0.84), TWTR: 30.85 (+0.53), MNKD: 3.05 (+0.04)
